TUCSON, Ariz., July 14, 2022 — Critical Path Institute (C-Path) has named Amanda Klein, Pharm.D., as Executive Director for its Transplant Therapeutics Consortium (TTC) effective immediately.
Klein is a clinical pharmacist with a unique and extensive clinical practice and scientific background. Before joining C-Path, she served patients with complex chronic diseases (diabetes, cirrhosis, hepatitis C, hypertension, dyslipidemia, heart failure, renal disease and comorbid mental health needs) in ambulatory and inpatient care settings. She joined C-Path in December 2019 as TTC Scientific Director and has been serving as TTC’s Interim Executive Director since January 2022. During this time, she has led the TTC team in advancing an innovative composite surrogate endpoint into regulatory qualification with back-to-back submissions to both the U.S. Food and Drug Administration and European Medicines Agency.
“Amanda is great asset and is uniquely suited to lead TTC,” said C-Path Chief Science Officer Klaus Romero, M.D., M.S., F.C.P. “She brings longstanding and insightful experience to the consortium and will continue to drive alignment among our diverse stakeholders in TTC, as well as support the organization’s overall mission and vision.”
C-Path’s TTC is a public-private partnership of diverse stakeholders across the global transplant field and regulatory agencies. Its mission is to accelerate the medical product development process for transplantation and provide a space for pre-competitive engagement. In addition, TTC facilitates discussion in the transplant field to identify challenges, prioritize solutions and develop tools that usher in new medical product development to meet the most pressing needs of transplant recipients.
Klein received a Bachelor of Science in Nutritional Sciences and a Doctor of Pharmacy from the University of Arizona. She completed residencies at the Phoenix Veterans Affairs Health Care System in ambulatory care and mental health and is a Clinical Instructor in the Department of Pharmacy Practice and Science at the University of Arizona College of Pharmacy. Klein currently precepts pharmacy students on rotation at C-Path. She is also an active member of the American Pharmacists Association and serves on the Care of Underserved Patients Advocacy Committee, serves as an Advisory Commissioner for the Arizona Health Education Center System and a member of the American Diabetes Association’s Overcoming Therapeutic Inertia workgroup. Her professional passions include polypharmacy, non-communicable disease management, rural health and integrative care.
“I joined C-Path because I wanted to reach patients on a macro level,” reflected Klein. “I am proud of our work in TTC through international collaboration, scientific exploration and deep regulatory strategy. I am grateful for this opportunity to serve the transplant community in this leadership role, ultimately helping patients living with a transplant thrive.”
For more information on C-Path’s TTC efforts, visit: https://c-path.org/programs/ttc
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and hundreds of pharmaceutical and biotech companies. C-Path U.S. is headquartered in Tucson, Arizona, C-Path in Europe is headquartered in Amsterdam, Netherlands and C-Path Ltd. operates from Dublin, Ireland with additional staff in multiple other locations. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 54.2% funded by the FDA/HHS, totaling $13,239,950, and 45.8% funded by non-government source(s), totaling $11,196,634. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.